The estimated Net Worth of Henrik Gronfeldt Sorensen is at least $120 Tausend dollars as of 10 January 2019. Mr. Sorensen owns over 50,000 units of Enochian Biosciences Inc stock worth over $35,000 and over the last 6 years he sold ENOB stock worth over $0. In addition, he makes $85,021 as Director at Enochian Biosciences Inc.
Sign up
Mr. Sorensen ENOB stock SEC Form 4 insiders trading
Henrik has made over 1 trades of the Enochian Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of ENOB stock worth $100,000 on 10 January 2019.
The largest trade he's ever made was buying 50,000 units of Enochian Biosciences Inc stock on 10 January 2019 worth over $100,000. On average, Henrik trades about 10,000 units every 0 days since 2019. As of 10 January 2019 he still owns at least 50,000 units of Enochian Biosciences Inc stock.
You can see the complete history of Mr. Sorensen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Henrik Gronfeldt-Sorensen biography
Henrik Gronfeldt-Sorensen serves as Director of the Company. He has been the Chief Executive Officer of RS Group ApS, RS Arving ApS, RS Family ApS and RS Newton ApS since October of 2012, and he has served as a director of Dr. Smood Group, Inc. since January of 2014. Mr. Gronfeldt-Sorensen has over 10 years’ experience in different CEO & management positions; Danske Bank in Denmark, and the Danish Bank Nykredit in France. RS Group of Companies is a family office in Denmark with global investments within real estate, charter business, food& beverage, private hospitals and biosciences industries. Mr. Gronfeldt-Sorensen holds an eMBA from University of Monaco (2011).
What is the salary of Henrik Sorensen?
As the Director of Enochian Biosciences Inc, the total compensation of Henrik Sorensen at Enochian Biosciences Inc is $85,021. There are 7 executives at Enochian Biosciences Inc getting paid more, with Mark Dybul having the highest compensation of $1,964,450.
How old is Henrik Sorensen?
Henrik Sorensen is 48, he's been the Director of Enochian Biosciences Inc since 2017. There are 9 older and no younger executives at Enochian Biosciences Inc. The oldest executive at Enochian Biosciences Inc is Carol Brosgart, 69, who is the Independent Director.
What's Henrik Sorensen's mailing address?
Henrik's mailing address filed with the SEC is HULSOVANG 12, RUNGSTED KYST, DENMARK, G7, 2960.
Insiders trading at Enochian Biosciences Inc
Over the last 7 years, insiders at Enochian Biosciences Inc have traded over $2,106,789 worth of Enochian Biosciences Inc stock and bought 552,919 units worth $3,888,612 . The most active insiders traders include Gregg H Alton, Rene Sindlev und Serhat Gumrukcu. On average, Enochian Biosciences Inc executives and independent directors trade stock every 91 days with the average trade being worth of $35,881. The most recent stock trade was executed by Serhat Gumrukcu on 18 May 2022, trading 253,493 units of ENOB stock currently worth $2,027,944.
What does Enochian Biosciences Inc do?
enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.
What does Enochian Biosciences Inc's logo look like?
Complete history of Mr. Sorensen stock trades at Enochian Biosciences Inc
Enochian Biosciences Inc executives and stock owners
Enochian Biosciences Inc executives and other stock owners filed with the SEC include:
-
Mark Dybul,
Executive Vice Chairman of the Board, Principal Executive Officer -
Luisa Puche,
Chief Financial Officer -
Dr. Mark R. Dybul M.D.,
Chief Exec. Officer & Director -
Luisa Puche,
Chief Financial Officer -
Evelyn D'An,
Independent Director -
James Sapirstein,
Independent Director -
Carl Sandler,
Independent Director -
Henrik Gronfeldt-Sorensen,
Director -
Rene Sindlev,
Independent Chairman of the Board -
Gregg Alton,
Independent Director -
Carol Brosgart,
Independent Director -
Dr. François Binette M.Sc., Ph.D.,
Exec. VP for R&D -
Greg Duczynski Ph.D.,
Sr. VP for Clinical Operations -
Dr. Serhat Gümrükcü,
Co-Founder & Inventor -
Tung Nguyen,
Head of Molecular Biology -
Dr. Wenshi Wang,
Sr. VP of Operations -
Dr. Serhat Gümrükcü,
Co-Founder & Inventor -
Francois Binette,
Executive VP for R&D -
Jayne Mc Nicol,
Director -
Eric Jean Marie Leire,,
-
Carl Forest Sandler,
-
Serhat Gumrukcu,
10% owner -
Anderson Wittekind William,
-
Science Llc Weird,